ReviewMolecular biology reports2026
Immunotherapy for oral cavity tumors: recent advances, key challenges, and future perspectives.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cavity tumors remain a major global health challenge, with poor outcomes in patients with locally advanced, recurrent, or metastatic disease despite advances in surgery, radiotherapy, chemotherapy, and targeted therapies. Immunotherapy has emerged as a potential strategy to restore antitumor immunity and overcome tumor-induced immune suppression. This narrative review synthesizes recent advances in immunotherapy for oral cavity tumors, focusing on immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitor (TKI) antibodies, near-infrared photoimmunotherapy (NIR-PIT), bispecific antibodies (BsAbs), oncolytic viruses (OVs), cytokine therapies, and adoptive cell therapies such as tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor (CAR)-T/natural killer (NK), and T cell receptor (TCR)-T therapy. The review also examines the pivotal role of the immunosuppressive tumor microenvironment (TME) in shaping treatment response and therapeutic resistance, highlighting the contributions of regulatory immune cells, cancer-associated fibroblasts (CAFs), hypoxia, extracellular matrix (ECM) remodeling, and immune exclusion. Current clinical evidence demonstrates meaningful survival benefits with programmed cell death protein 1 (PD-1) inhibitors in recurrent/metastatic disease and expanding opportunities for perioperative immunotherapy, while numerous emerging modalities remain under active clinical investigation. However, durable responses remain limited by tumor heterogeneity, inadequate immune cell trafficking, antigen escape, manufacturing challenges, and the lack of reliable predictive biomarkers. Future progress will likely depend on biomarker-guided patient selection, rational combination strategies, and engineered cellular therapies that can overcome microenvironment-mediated resistance. Collectively, these findings support continued investigation of personalized, multimodal immunotherapy as a viable avenue for improving outcomes in patients with oral squamous cell carcinoma (OSCC).
Indexed as
Identifiers
42862405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.